X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (197) 197
cyp17 (184) 184
index medicus (176) 176
male (154) 154
prostate cancer (123) 123
abiraterone acetate (94) 94
oncology (94) 94
prostatic neoplasms - drug therapy (79) 79
steroid 17-alpha-hydroxylase - antagonists & inhibitors (77) 77
animals (65) 65
i clinical-trial (65) 65
abiraterone (56) 56
pharmacology & pharmacy (56) 56
inhibitor (54) 54
chemistry, medicinal (51) 51
docetaxel (51) 51
prostate-cancer (48) 48
steroid 17-alpha-hydroxylase - metabolism (45) 45
antitumor-activity (44) 44
endocrinology & metabolism (44) 44
androgen receptor (42) 42
cytochrome p-450 (40) 40
biochemistry & molecular biology (39) 39
ketoconazole (39) 39
testosterone (39) 39
cancer (38) 38
chemotherapy (37) 37
prostatic neoplasms, castration-resistant - drug therapy (37) 37
androgens (36) 36
biological evaluation (36) 36
middle aged (36) 36
aged (34) 34
castration (34) 34
orchiectomy (34) 34
androstenes (31) 31
therapy (31) 31
treatment outcome (31) 31
antineoplastic agents - therapeutic use (30) 30
cyp17 inhibitors (29) 29
increased survival (29) 29
prostatic neoplasms - pathology (29) 29
care and treatment (28) 28
androgen antagonists - therapeutic use (27) 27
enzyme inhibitors - pharmacology (27) 27
female (27) 27
human 17-alpha-hydroxylase-17,20-lyase cyp17 (27) 27
prostatic neoplasms - surgery (27) 27
castration-resistant prostate cancer (26) 26
aged, 80 and over (25) 25
article (25) 25
expression (25) 25
plus prednisone (25) 25
receptors, androgen - metabolism (25) 25
resistant prostate-cancer (25) 25
steroid 17-alpha-hydroxylase - genetics (25) 25
cell line, tumor (24) 24
phase-ii (24) 24
steroidal inhibitors (24) 24
androstenols - therapeutic use (23) 23
drug therapy (23) 23
research (23) 23
structure-activity relationship (23) 23
urology & nephrology (23) 23
acetate (22) 22
metastasis (22) 22
prostatic neoplasms - metabolism (22) 22
enzalutamide (21) 21
in-vitro (21) 21
inhibitors (21) 21
medicine & public health (21) 21
androgens - metabolism (20) 20
antiandrogen withdrawal (20) 20
prostatic neoplasms - enzymology (20) 20
prostatic neoplasms, castration-resistant - pathology (20) 20
rats (20) 20
androgen (19) 19
men (19) 19
models, molecular (19) 19
survival (19) 19
androstadienes - therapeutic use (18) 18
antiandrogen (18) 18
antineoplastic agents, hormonal - therapeutic use (18) 18
adult (17) 17
clinical trials as topic (17) 17
derivatives (17) 17
dose-response relationship, drug (17) 17
enzyme inhibitors - chemistry (17) 17
neoplasm metastasis (17) 17
aromatase inhibitors (16) 16
chemistry, organic (16) 16
enzyme inhibitors - therapeutic use (16) 16
enzymes (16) 16
mice (16) 16
mitoxantrone (16) 16
pharmacokinetics (16) 16
physiological aspects (16) 16
progression (16) 16
prostate (16) 16
taxoids - therapeutic use (16) 16
antineoplastic agents - chemistry (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Steroids, ISSN 0039-128X, 10/2019, Volume 150, p. 108384
Both AR and CYP17 are important targets for blocking androgen signaling, and it has been accepted that multifunctional drugs have a low risk of drug resistance... 
CYP17 inhibitors | AR antagonists | Prostate cancer | Dual target | ANDROGEN RECEPTOR | POLYPHARMACOLOGY | BIOCHEMISTRY & MOLECULAR BIOLOGY | ENDOCRINOLOGY & METABOLISM | BIOLOGICAL EVALUATION | RESISTANCE | ANTIANDROGENS | AGENTS
Journal Article
Clinical Chemistry and Laboratory Medicine (CCLM), ISSN 1434-6621, 09/2019, Volume 57, Issue 10, pp. 253 - 254
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 09/2019, Volume 18, Issue 9, pp. 759 - 767
Journal Article
BMC Urology, ISSN 1471-2490, 12/2018, Volume 18, Issue 1, pp. 110 - 8
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2018, Volume 119, Issue 9, pp. 1052 - 1059
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 2018, Volume 61, Issue 20, pp. 9229 - 9245
Cytochrome P450 (CYP) 1B1 is involved in the bioactivation of procarcinogens and drug resistance. To obtain selective CYP1B1 inhibitors over CYP1A1, we... 
BREAST-CANCER | 17-ALPHA-HYDROXYLASE/17,20-LYASE CYP17 | CHEMISTRY, MEDICINAL | METABOLISM | PROSTATE-CANCER | ESTRADIOL | RESISTANCE | TYPE-1 17-BETA-HYDROXYSTEROID-DEHYDROGENASE | CHEMICAL-SYNTHESIS | ESTRONE | EXPRESSION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 30, pp. 3058 - 3058
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 30, pp. 3064 - 3065
Journal Article
by Ke, JQ and Shen, Z and Li, M and Peng, C and Xu, P and Wang, MM and Zhu, Y and Zhang, XF and Wu, DB
ONCOLOGY LETTERS, ISSN 1792-1074, 10/2018, Volume 16, Issue 4, pp. 4577 - 4585
Prostaglandin E2 (PGE2) is the most common prostaglandin in the human body, meaning that its malfunction impacts on the development of numerous diseases.... 
CELLS | CYP17 INHIBITORS | CYCLOOXYGENASE-2 | CONSTITUTIVE ACTIVATION | signal transducer and activator of transcription 3 | 17-BETA-ESTRADIOL | STAT3 ACTIVATION | cytochrome P450 17 hydroxylase | ONCOLOGY | prostaglandin E2 | BIOSYNTHESIS | endometrial cancer | GENE-EXPRESSION | JAK2/STAT3 | MODULATION
Journal Article
Journal Article
Journal Article